November 10, 2021

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates and baseline data from ATH-1017’s ongoing Phase 2 and Phase 2/3 clinical trials at the 2021 CTAD

November 10, 2021

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

Balanced baseline characteristics in ACT-AD and LIFT-AD to date – – Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small

November 8, 2021

Athira Pharma to Present at Upcoming Investor Conferences

Stifel 2021 Virtual Healthcare Conference- – Jefferies 2021 London Healthcare Conference- BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop

October 29, 2021

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function Webinar to be held Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET BOTHELL, Wash., Oct. 29, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on

October 22, 2021

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc.  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced today that it has completed

October 21, 2021

Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas’s Doctoral Research Conference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) —   Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical